Navigation Links
Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Date:12/3/2013

DA Update Conference Call" and reference conference passcode 75822572.  If you are unable to listen to the live webcast, a teleconference replay will be available through Wednesday, December 11, 2013.  Interested parties can access the replay by dialing 888-286-8010 and entering the conference passcode 13352784.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Thursday, December 19, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit BiosciencesAmbit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory AML and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations re
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
2. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
3. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
4. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
5. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 /PRNewswire-iReach/ -- Harmony Foundation, Colorado,s ... Estes Park , will break ground for a new ... am on Harmony,s campus. The public is welcome to attend ... of Harmony,s $10 million Support & Renew Capital Campaign ... and complex addiction rates in Colorado . ...
(Date:7/14/2014)...  More than any other generation, Millennials born in the ... but their eyes don,t. These mobile devices demand a type ... eye has not evolved to cope with them. The gap ... comfortably often results in tired eyes, focusing problems, headaches and ... Now ZEISS has invented a new type of lens for ...
(Date:7/14/2014)...  GenSpera, Inc. (OTCQB: GNSZ), a leader in ... announces that Kareg Corporation,s Director of Research, ... research report on  the company. ... Kareg Corporation, Initiating Coverage with a Speculative Buy ... http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf GNSZ is attractive ...
Breaking Medicine Technology:Harmony Foundation Breaking Ground on Addiction Health Center 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6
(Date:7/14/2014)... Academy, senescent is he who "begins to age". But ... is senescence not a synonym of ageing, it is ... is such a badly named physiological process that those ... another name. That is the case of Manuel Serrano, ... of the world,s leading experts on senescence, who has ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 The ... & Services [Physical Security, Life Safety, Facility Management], ... Worldwide Forecast & Analysis (2014 - 2019)” defines ... with an in-depth analysis and forecasting of revenues. ... market, various restraints and opportunities impacting it, along ...
(Date:7/14/2014)... into an agreement with one of the world,s ... candidates for the detection and treatment of cancer. ... antibody discovery and Roche,s expertise in developing monoclonal ... of improved treatment for cancer, a leading cause ... use of BTI,s discovery of a new mechanism ...
(Date:7/14/2014)... Secure Decisions, a leading provider of assessment ... Software Assurance Marketplace (SWAMP) to build a powerful and ... everyday life. , The SWAMP, implemented by a group ... Institute for Research, is funded by the Department of ... by building a free facility with a diverse repository ...
(Date:7/14/2014)... with improving vision, cataract surgery may slow mental decline ... dementia, a new study suggests. Better eyesight also ... "These preliminary results indicate that improved vision can have ... their loved ones, both visual and non-visual," said Dr. ... Hospitals Case Medical Center, in Ohio. Cataract surgery ...
Breaking Medicine News(10 mins):Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 2Health News:Manuel Serrano proposes a new vision of a process wrongly associated with ageing 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2
... , Preliminary research on Fusarium , a group ... animals, shows how these microbes travel through the air. ... preliminary research, there will be a better understanding about ... biologists are steering their efforts towards a new aerobiological ...
... malaria vaccine that uses the entire malaria parasite has proven ... in a clinical trial, according to a new study co-authored ... Center for Vaccine Development. The vaccine is unique in that ... vaccines consist of just one or at most a few ...
... Institute in Boston and the Scripps Research Institute in ... powerful anti-diabetic effects, yet apparently free at least ... current diabetes medications. The researchers say that their ... 2 diabetes, which affects more than 25 million children ...
... HealthDay Reporter , FRIDAY, Sept. 9 (HealthDay News) -- ... were to meet Friday to discuss problems linked to ... Boniva and Reclast. These drugs, known as ... osteoporosis. But researchers have linked long-term use with a ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- Many ... infant. But sometimes that concern develops into an obsession over ... that condition postpartum obsessive compulsive disorder. It can drive women ... true, such as endlessly washing the infant to stave off ...
... at the University of Ottawa Heart Institute (UOHI) have ... and exports cholesterol from cells. A team ... Biology Laboratory, UOHI, has shown that autophagy, a pathway ... accumulated in artery walls. This process facilitates the removal ...
Cached Medicine News:Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 2Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 3Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 4Health News:Whole-parasite malaria vaccine shows promise in University of Maryland School of Medicine clinical trial 5Health News:New twist in diabetes drugs could reduce life-threatening side effects 2Health News:New twist in diabetes drugs could reduce life-threatening side effects 3Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:When Protecting Baby Becomes an Obsession 2Health News:When Protecting Baby Becomes an Obsession 3Health News:Researchers find process that clears cholesterol and could reverse major cause of heart attack 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: